Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tumors: early-phase trial registry
3 of 21 indexed Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 3 currently recruiting · #797 of 28,707 conditions by registered trial count
Tumors: 21 US clinical trials tracked, 3 recruiting.
Tumors is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Eisai, running 2 of these trials.
Enrollment posture brief
Registry condition tumors
OPEN 3 | RECR 14% | LATE 1 | EARLY 17 | RANK #797 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Tumors lists 3 open slots (14% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tumors is recruiting below its size-band peers.
3 of 21 indexed trials (14.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Tumors trials is spread across many organizations.
Eisai accounts for 2 of 21 trials (9.5%). 19 distinct sponsors appear on at least one study for this condition label.
-
Typical Tumors enrolment sits around 66 participants.
Median target enrolment is 66 among the 21 trials that report a genuine target (sentinel values excluded). 11 of those (52.4%) plan for fewer than 100 participants.
-
Tumors research is mostly interventional.
19 interventional and 2 observational studies make up this index (90.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
XACT ACE Observational Registry
Xact Robotics
NCT04950959
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
M.D. Anderson Cancer Center
NCT05733091
HP Pyruvate MRI in Cancers
University of Maryland, Baltimore
NCT05697406
Perioperative Risk Study
Fox Chase Cancer Center
NCT02456389
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
NCT00838201
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai
NCT02501096
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Kiadis Pharma
NCT00248404
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
NCT02549937
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
NCT00495144
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
AstraZeneca
NCT00127829
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai
NCT02686164
Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
INSYS Therapeutics
NCT00024492
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Astellas Pharma
NCT01409135
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
Bristol-Myers Squibb
NCT00437437
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
Peregrine Pharmaceuticals
NCT00129337
A Study of AMG 820 in Subjects With Advanced Solid Tumors
AmMax Bio
NCT01444404
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Ludwig Institute for Cancer Research
NCT00299728
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
NCT01235897
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Novartis Pharmaceuticals
NCT00421044
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tumors page
21 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eisai sponsors the most Tumors trials on record, review their full trial history before evaluating a specific study. See Eisai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tumors condition card totals 21 registered trials; most-linked intervention Lenvatinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.